**Objective**: To determine whether low levels of 25-hydroxyvitamin D (25(OH)D) contribute to the increased risk of postpartum multiple sclerosis (MS) relapses.

**Design**: Prospective cohort study.

**Setting**: Outpatients identified through membership records of Kaiser Permanente Northern California or Stanford University outpatient neurology clinics.

**Patients**: Twenty-eight pregnant women with MS.

**Interventions**: We prospectively followed up patients through the postpartum year and assessed exposures and symptoms through structured interviews. Total serum 25(OH)D levels were measured using the DiaSorin Liaison Assay during the third trimester and 2, 4, and 25(OH)D levels were measured using the DiaSorin symtoms through structured interviews. Total serum levels of 25(OH)D and relapse rate.

**Main Outcome Measures**: Levels of 25(OH)D and relapse rate.

**Results**: Fourteen (50%) women breastfed exclusively, and 12 women (43%) relapsed within 6 months after giving birth. During pregnancy, the average 25(OH)D levels were 25.4 ng/mL (range, 13.7-42.6) and were affected only by season (P=.009). In contrast, in the postpartum period, 25 (OH)D levels were significantly affected by breastfeeding and relapse status. Levels of 25(OH)D remained low in the exclusive breastfeeding group, yet rose significantly in the nonexclusive breastfeeding group regardless of season (P=.007, unadjusted; P=.02, adjusted for season). By 4 and 6 months after childbirth, 25(OH)D levels were, on average, 5 ng/mL lower in the women who breastfed exclusively compared with the nonbreastfeeding group (P=.001).

**Conclusions**: Pregnancy and exclusive breastfeeding are strongly associated with low 25(OH)D levels in women with MS. However, these lower vitamin D levels were not associated with an increased risk of postpartum MS relapses. These data suggest that low vitamin D in isolation is not an important risk factor for postpartum MS relapses.


**ORIGINAL CONTRIBUTION**

**Vitamin D, Pregnancy, Breastfeeding, and Postpartum Multiple Sclerosis Relapses**

Annette Langer-Gould, MD, PhD; Stella Huang, MS, DO; Stephen K. Van Den Eeden, PhD; Rohit Gupta, BS; Amethyst D. Leimpeter, MS; Kathleen B. Albers, MPH; Ron Horst, PhD; Bruce Hollis, PhD; Lawrence Steinman, MD; Lorene M. Nelson, PhD

**METHODS**

**Subjects and Study Design**

Details of the subject recruitment and study design have previously been described.5,6 Briefly,
we recruited 32 pregnant women with clinically definite MS from Northern California between 2002 and 2005. Details of the study and testing procedures were explained to each subject, and written informed consent was obtained. The institutional review boards at Stanford University and Kaiser Foundation Research Institute approved this study.

Subjects donated blood and completed structured interviewer-administered questionnaires at study entry, during the remaining trimesters of pregnancy, and at 2, 3, 6, 9, and 12 months after childbirth. Relapses were defined according to standard criteria and were confirmed by the treating physician.

Levels of 25-hydroxyvitamin D (25(OH)D) were measured using the Food and Drug Administration–approved direct, competitive chemiluminescence immunoassay DiaSorin LIAISON platform1 performed at Heartland Assays Inc (Ames, Iowa). Serum samples obtained during the third trimester and 2, 4, and 6 months after childbirth were stored at −80°C and were analyzed for all subjects who had at least 1 pregnancy and 1 postpartum sample available (n=28). Very few samples were missing, and 94% (105 of 112) of samples from 28 women were included in the analysis.

STATISTICAL ANALYSIS

The data were analyzed using longitudinal data methods aimed at identifying patterns over time while accounting for interindividual and intraindividual variation. To determine whether 25(OH)D levels change during pregnancy and the postpartum period (or in relation to the onset of relapse symptoms), piecewise linear mixed models were used. The models were hypothesis driven and included 25(OH)D in nanograms per milliliter as the dependent variable and time in days relative to the day of delivery (or onset of relapse symptoms), relapse within the first 6 months after childbirth (yes/no), exclusive breastfeeding (yes/no), and season of blood draw (April-September vs October-March) as the independent variables. Exclusive breastfeeding was defined as no regular formula feedings for the first 6 months after childbirth. To identify breakpoints in the data, a nonparametric method for estimating local regression (loess) was set at .01. All statistical analyses were performed using SAS version 9 (Cary, North Carolina).

To graphically depict the differences in absolute and relative values of immunological parameters, we recruited 32 pregnant women with clinically definite MS from Northern California between 2002 and 2005. Details of the study and testing procedures were explained to each subject, and written informed consent was obtained. The institutional review boards at Stanford University and Kaiser Foundation Research Institute approved this study.

Subjects donated blood and completed structured interviewer-administered questionnaires at study entry, during the remaining trimesters of pregnancy, and at 2, 3, 6, 9, and 12 months after childbirth. Relapses were defined according to standard criteria and were confirmed by the treating physician.

Levels of 25-hydroxyvitamin D (25(OH)D) were measured using the Food and Drug Administration–approved direct, competitive chemiluminescence immunoassay DiaSorin LIAISON platform1 performed at Heartland Assays Inc (Ames, Iowa). Serum samples obtained during the third trimester and 2, 4, and 6 months after childbirth were stored at −80°C and were analyzed for all subjects who had at least 1 pregnancy and 1 postpartum sample available (n=28). Very few samples were missing, and 94% (105 of 112) of samples from 28 women were included in the analysis.

STATISTICAL ANALYSIS

The data were analyzed using longitudinal data methods aimed at identifying patterns over time while accounting for interindividual and intraindividual variation. To determine whether 25(OH)D levels change during pregnancy and the postpartum period (or in relation to the onset of relapse symptoms), piecewise linear mixed models were used. The models were hypothesis driven and included 25(OH)D in nanograms per milliliter as the dependent variable and time in days relative to the day of delivery (or onset of relapse symptoms), relapse within the first 6 months after childbirth (yes/no), exclusive breastfeeding (yes/no), and season of blood draw (April-September vs October-March) as the independent variables. Exclusive breastfeeding was defined as no regular formula feedings for the first 6 months after childbirth. To identify breakpoints in the data, a nonparametric method for estimating local regression (loess) was set at .01. All statistical analyses were performed using SAS version 9 (Cary, North Carolina).

To graphically depict the differences in absolute and relative values of immunological parameters, we compared the mean (standard deviations [SD]) of normally distributed variables were compared using 2-sample t tests; for variables with nonparametric distributions, the Wilcoxon rank sum test was used. Binary or categorical variables were analyzed using χ² with Fisher exact test. To adjust for multiple comparisons, α was set at .01. All statistical analyses were performed using SAS version 9 (Cary, North Carolina).

To graphically depict the differences in absolute and relative values of immunological parameters, we compared the mean (standard deviations [SD]) of normally distributed variables were compared using 2-sample t tests; for variables with nonparametric distributions, the Wilcoxon rank sum test was used. Binary or categorical variables were analyzed using χ² with Fisher exact test. To adjust for multiple comparisons, α was set at .01. All statistical analyses were performed using SAS version 9 (Cary, North Carolina).

To graphically depict the differences in absolute and relative values of immunological parameters, we compared the mean (standard deviations [SD]) of normally distributed variables were compared using 2-sample t tests; for variables with nonparametric distributions, the Wilcoxon rank sum test was used. Binary or categorical variables were analyzed using χ² with Fisher exact test. To adjust for multiple comparisons, α was set at .01. All statistical analyses were performed using SAS version 9 (Cary, North Carolina).

RESULTS

Detailed demographic and clinical characteristics of participants have been previously described. Briefly, most participants (93%) were white, all but 1 took prenatal vitamins during pregnancy, 14 (50%) breastfed exclusively, and 17 (71%) relapsed within 12 months after childbirth, most of whom (n=12) relapsed within 6 months. Additional baseline and clinical characteristics of women with MS who breastfed exclusively for at least the first 2 months and those who did not breastfeed are presented in the Table.

Table. Characteristics of Study Participants at Onset of Pregnancy, During Pregnancy, and in the Postpartum Period

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Exclusive Breastfeeding (n=14)</th>
<th>Nonexclusive Breastfeeding (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean (SD)</td>
<td>33.0 (3.5)</td>
<td>32.2 (4.5)</td>
</tr>
<tr>
<td>Disease duration, y, median (range)</td>
<td>4.6 (1.6-20.8)</td>
<td>6.2 (2.1-15.8)</td>
</tr>
<tr>
<td>White race</td>
<td>13 (93)</td>
<td>13 (93)</td>
</tr>
<tr>
<td>Samples obtained during summer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third trimester</td>
<td>7 (50)</td>
<td>8 (57)</td>
</tr>
<tr>
<td>6 mo after childbirth</td>
<td>5 (36)</td>
<td>5 (36)</td>
</tr>
<tr>
<td>Prenatal vitamin use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third trimester</td>
<td>14 (100)</td>
<td>13 (93)</td>
</tr>
<tr>
<td>After childbirth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-2 mo</td>
<td>3 (21)</td>
<td>4 (29)</td>
</tr>
<tr>
<td>≥6 mo</td>
<td>7 (50)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Women with relapses after childbirth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-1 mo</td>
<td>1 (7)</td>
<td>4 (29)</td>
</tr>
<tr>
<td>2-3 mo</td>
<td>1 (7)</td>
<td>4 (29)</td>
</tr>
<tr>
<td>4-5 mo</td>
<td>0</td>
<td>2 (14)</td>
</tr>
<tr>
<td>≥6 mo</td>
<td>3 (21)</td>
<td>2 (14)</td>
</tr>
</tbody>
</table>

*At onset of pregnancy.

Figure 1. Serum 25(OH)D levels during pregnancy and exclusive breastfeeding in women with multiple sclerosis. Depicted are the mean (standard deviation) of serum 25(OH)D levels in women with multiple sclerosis who breastfed exclusively for at least 2 months (BF, n=14) and those who did not (NBF, n=14) during the third trimester of pregnancy and the postpartum period. *P<.001, unadjusted; †P=.02, adjusted for season; ‡P=.001 unadjusted; P=.04, adjusted for season. To convert 25(OH)D to nanomoles per liter, multiply by 2.496.

Pregnancy and exclusive breastfeeding were strongly associated with low 25(OH)D levels (Figure 1). During pregnancy, 20 women (71%) were vitamin D insufficient (<30 ng/mL [to convert to nanomoles per liter, multiply by 2.496]) and the average 25(OH)D levels were 25.4 ng/mL (range, 13.7-42.6). In the postpartum period, 25(OH)D levels remained low among the exclusive breastfeeding group yet rose significantly in the nonexclusive breastfeeding group (Figure 1; P=.007, unadjusted; P=.02, adjusted for season; for rise from pregnancy to 4 months after childbirth). By 4 and 6 months after childbirth, 25(OH)D levels were an average of 5 ng/mL lower in the women who breastfed exclusively
pared with women who were relapse-free during pregnancy and the first 6 months after childbirth (n=16) during the third trimester of pregnancy and the postpartum period. *P=.04, unadjusted; P=.04 adjusted for season. To convert 25(OH)D to nanomoles per liter, multiply by 2.496.

We speculate that the most likely explanation for our apparently paradoxical finding (low vitamin D does not increase the risk of postpartum relapse) is that factors associated with pregnancy and lactation modulate and perhaps override the proinflammatory effects of low vitamin D. That immunomodulatory interactions between vitamin D and sex hormones and/or female sex might exist is supported by data showing that vitamin D and progesterone enhance inactivation of estrogen diol in monocytes through regulation of key estrogen metabolizing enzymes.

In this prospective cohort study, we found that women with MS had low vitamin D levels during pregnancy and lactation but that these lower levels were not associated with an increased risk of relapses. We found that vitamin D levels rose around the time of relapse and were higher 3 to 6 months after childbirth in women who relapsed. These findings suggest that low vitamin D in isolation is not an important predictor of postpartum MS relapses and imply that other factors associated with pregnancy and lactation may be important modulators of the relationship between vitamin D and MS disease activity.

We do not believe that higher vitamin D levels increase the risk of postpartum relapses, as the rise we observed did not appear to occur prior to the onset of symptoms and the findings were of marginal statistical significance after accounting for season. Instead, we think this apparent inverse association is a reflection of the fact that most of the women who relapsed in this study also did not breastfeed or did so only briefly.

On the surface, our finding that low vitamin D is not an important risk factor for postpartum MS relapses, thereby implying that vitamin D supplementation during pregnancy and lactation is unlikely to affect the risk of postpartum MS relapses, may seem inconsistent with studies that found an association between low serum vitamin D and MS relapses and MS disability. However, our findings seem logical when other lines of evidence are considered. First, it is well known that women who are pregnant or lactating are at high risk of vitamin D deficiency. Second, it is also well established that pregnant women with MS have a low risk of relapse and that lactation does not increase the risk of relapses. Third, there is no evidence that the hormonal effects of pregnancy or lactation are different in women with MS compared with healthy women. Finally, dark-skinned individuals are at higher risk of vitamin D insufficiency, yet have a lower risk of MS than white individuals, indicating that low vitamin D in isolation is not always associated with increased risk of MS.

In contrast, postpartum MS relapses were not associated with low 25(OH)D (Figure 2 and Figure 3). If anything, by 3 to 6 months after childbirth, 25(OH)D levels were marginally higher among the women who relapsed within the first 6 months after childbirth compared with women who were relapse-free during the corresponding period (Figure 2; P=.04 unadjusted; P=.04 adjusted for season). In women with postpartum relapses, 25(OH)D levels rose an average of 4 ng/mL around the time of relapse (Figure 3; P=.02, unadjusted; P=.005, adjusted for season).
Our study is limited by the small sample and inability to account for sun exposure, though we accounted for most factors that influence serum vitamin D levels (eg, race/ethnicity, season, and prenatal vitamin use). In addition, because most of the women in our study were vitamin D insufficient, we cannot exclude the possibility that much higher 25(OH)D levels may be protective. Thus, our findings should be confirmed in a larger study.

Our finding that low vitamin D is not a risk factor for MS relapses in pregnant and lactating women suggests that increasing vitamin D levels during pregnancy and the postpartum period in women with MS is unlikely to affect the risk of postpartum relapses. Therefore, our findings imply that the recommended dose of vitamin D supplementation for women with MS during pregnancy and lactation should be the same as for women who are not. Our results suggest that future studies aimed at identifying and unraveling the relationship between vitamin D, pregnancy/lactation-related hormones, and regulation of MS inflammation may reveal novel insights into MS pathophysiology.

Accepted for Publication: March 3, 2010.

Correspondence: Annette Langer-Gould, MD, PhD, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101 (annette.mlanger-gould@kp.org).

Author Contributions: Study concept and design: Langer-Gould, Van Den Eeden, and Steinman.
Acquisition of data: Langer-Gould, Huang, Van Den Eeden, Gupta, Leimpeter, Albers, and Horst.
Analysis and interpretation of data: Langer-Gould, Van Den Eeden, Hollis, Steinman, and Nelson.
Drafting of the manuscript: Langer-Gould, Van Den Eeden, Horst, Hollis, and Steinman.
Critical revision of the manuscript for important intellectual content: Langer-Gould, Huang, Van Den Eeden, Gupta, Leimpeter, Albers, Hollis, Steinman, and Nelson.
Statistical analysis: Langer-Gould, Van Den Eeden, and Nelson.
Obtained funding: Langer-Gould, Van Den Eeden, and Steinman.
Administrative, technical, and material support: Langer-Gould, Huang, Van Den Eeden, Gupta, Leimpeter, Albers, and Hollis.

Financial Disclosure: None reported.

Funding/Support: This study was supported by K23 grant NS43207 from the National Institute of Neurologic Disorders and Stroke of the National Institutes of Health and a Wadsworth Foundation Young Investigator’s Award (Dr Langer-Gould).

REFERENCES